Neuroone Medical Technologies is trading 14% up now at $1.93, extending gains following positive physician experience data from a Mayo Clinic study of epilepsy patients treated with its OneRF brain ablation system.
- The study highlighted meaningful reductions in seizure frequency and improved quality of life, with high tolerability and no serious long-term complications reported.
- The clinical success has significantly bolstered investor confidence in the company's specialized brain ablation technology.
- Broader U.S. market gains are providing an additional tailwind for the stock's continued upward momentum.